Abstract
Ghrelin is a stomach-derived hormone that acts at the ghrelin receptor (formerly called the Growth Hormone Secretagogue (GHS)-1a receptor) in multiple tissues throughout the body, exhibiting pleotropic effects potentially beneficial as a treatment in human disease states. Given its properties including increasing appetite, decreasing systemic inflammation, decreasing vascular resistance, increasing cardiac output, and increasing growth hormone and IGF-1 levels, ghrelin has been tested as a treatment in animal models of multiple disease states that produce the deficits in these processes. Thus, the efficacy of ghrelin has been testing in diseases involving anorexia, negative energy balance, cardiovascular compromise, systemic inflammation and gastroparesis. These diseases include cancer cachexia, chronic heart failure, chronic renal failure, chemotherapy, arthritis, gastroparesis and inflammatory bowel disease. Across this wide variety of diseases treatment with ghrelin and ghrelin agonists have produced benefits, though given ghrelin’s widespread effects, the exact mechanisms behind ghrelin’s action in these settings is frequently difficult to determine. Further investigation using animal models may help to determine mechanisms that are most operative in these disease states and narrow treatment parameters helpful for human application.
Keywords: Ghrelin, cachexia, animal models, treatment, cancer, chronic heart failure, chronic kidney disease, Growth Hormone Secretagogue, appetite, inflammation.
Current Pharmaceutical Design
Title:The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Volume: 18 Issue: 31
Author(s): Mark D. DeBoer
Affiliation:
Keywords: Ghrelin, cachexia, animal models, treatment, cancer, chronic heart failure, chronic kidney disease, Growth Hormone Secretagogue, appetite, inflammation.
Abstract: Ghrelin is a stomach-derived hormone that acts at the ghrelin receptor (formerly called the Growth Hormone Secretagogue (GHS)-1a receptor) in multiple tissues throughout the body, exhibiting pleotropic effects potentially beneficial as a treatment in human disease states. Given its properties including increasing appetite, decreasing systemic inflammation, decreasing vascular resistance, increasing cardiac output, and increasing growth hormone and IGF-1 levels, ghrelin has been tested as a treatment in animal models of multiple disease states that produce the deficits in these processes. Thus, the efficacy of ghrelin has been testing in diseases involving anorexia, negative energy balance, cardiovascular compromise, systemic inflammation and gastroparesis. These diseases include cancer cachexia, chronic heart failure, chronic renal failure, chemotherapy, arthritis, gastroparesis and inflammatory bowel disease. Across this wide variety of diseases treatment with ghrelin and ghrelin agonists have produced benefits, though given ghrelin’s widespread effects, the exact mechanisms behind ghrelin’s action in these settings is frequently difficult to determine. Further investigation using animal models may help to determine mechanisms that are most operative in these disease states and narrow treatment parameters helpful for human application.
Export Options
About this article
Cite this article as:
D. DeBoer Mark, The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism, Current Pharmaceutical Design 2012; 18 (31) . https://dx.doi.org/10.2174/138161212803216951
DOI https://dx.doi.org/10.2174/138161212803216951 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic:Anabolic Androgenic Steroids (AAS) as Doping Agents: Chemical Structures,Metabolism, Cellular Responses, Physiological and Pathological Effects (Guest Editor: V. Fineschi)]
Mini-Reviews in Medicinal Chemistry Myocardial Ischemia/Reperfusion Injury: Potential of TRPV1 Agonists as Cardioprotective Agents
Cardiovascular & Hematological Disorders-Drug Targets Updated Research and Applications of Small Molecule Inhibitors of Keap1-Nrf2 Protein-Protein Interaction: a Review
Current Medicinal Chemistry Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets Fetzima (levomilnacipran), a Drug for Major Depressive Disorder as a Dual Inhibitor for Human Serotonin Transporters and Beta-Site Amyloid Precursor Protein Cleaving Enzyme-1
CNS & Neurological Disorders - Drug Targets Role of Nitric Oxide and Mitochondrial Nitric Oxide Synthase in Energy Adaptive Responses
Current Cardiology Reviews Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Synthesis and Antiproliferative Activity of New Polyoxo 2-Benzyl-2,3- dihydrobenzofurans and Their Related Compounds
Letters in Drug Design & Discovery Endothelial Lipase: A Key Player in HDL Metabolism Modulates Inflammation and Atherosclerotic Risk
Mini-Reviews in Medicinal Chemistry Congenital Parenchymal Lesions of the Lung
Current Respiratory Medicine Reviews Epidemiology, Evolution, Transmission, and Therapeutics of COVID-19 Outbreak: An Update on the Status
Coronaviruses Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Vascular Endothelin and Hypertension - From Receptors to Medicine
Current Hypertension Reviews Bioactive Components and Pharmacological Action of Wikstroemia indica (L.) C. A. Mey and Its Clinical Application
Current Pharmaceutical Biotechnology Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Bone Loss and Osteoporosis are Associated with Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Vitamin D Intake and Obesity in Occupational Asthma Patients and the Need for Supplementation
Endocrine, Metabolic & Immune Disorders - Drug Targets Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Pharmacotherapy & Surgical Interventions Available for Obesity Management and Importance of Pancreatic Lipase Inhibitory Phytomolecules as Safer Anti-Obesity Therapeutics
Mini-Reviews in Medicinal Chemistry The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design